SYMPOSIA

Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org
Poster Presentations
intervention (p = 0.144), severity of combined physical-mental symptoms before intervention (p = 0.242) in the first group. There was a
significant difference among the severity of physical (p= 0.000), mental (p= 0.000), combined physical-mental symptoms (p= 0.000) before
and after intervention. The reduction in severity of physical, mental, and combined physical-mental symptoms after intervention was
significant between the two groups (p= 0.000).
Conclusion: Based on our results 1000mg/day fish oil may reduce the severity of physical, mental, and combined physical-mental
symptoms of PMS.
Key words: Premenstrual syndrome, fish oil, placebo, physical symptom, mental symptom
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S134-5
[PP-024] Ref. No: 145
Improvement of risperidone-induced hyperprolactinemia with the addition
of aripiprazole: Case report
Medine Gıynaş Ayhan, Faruk Uguz, Nazmiye Kaya
Department of Psychiatry, Selcuk University,Meram School of Medicine, Konya, Turkey.
E-mail: drmedineayhan@gmail.com
Objective: Hyperprolactinemia is an important side effect of antipsychotic treatment. All typical antipsychotics and some atypical
antipsychotics such as risperidone and amisulpiride have been shown to cause marked elevation in serum prolactin levels, whereas most
other atypical antipsychotics such as quetiapine, olanzapine, clozapine, ziprasidone, and aripiprazole appear to have little or no effect on
serum prolactin levels. Hyperprolactinemia can lead to gynecomastia, galactorrhea, sexual dysfunction, infertility, oligomenorrhea, and
amenorrhea. It also reduces the bone mineral density and contributes to osteoporosis in the long term. These important side effects cause
patients in remission not to continue treatment.
Case: We report two clinical cases of risperidone-induced hyperprolactinemia and amenorrhea, who with treatment by the partial
dopamine agonist aripiprazole, showed prolactin normalization.
Conclusion: Addition of aripiprazole to treatment may be considered as a first option in hyperprolactinemia cases with significant
improvement in psychotic symptoms.
Key words: Hyperprolactinemia, amenorrhea, antipsychotic, risperidone, aripiprazole
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S135
[PP-025] Ref. No: 146
Atomoxetine for the treatment of ADHD in young adults with an assessment
of associated functional outcomes
Murat Altın 1 , Levent Alev 1 , Todd M. Durell 2 , Leonard A. Adler 3 , Dave W. Williams 2 , Ahmed Deldar 2 , James J. Mcgough 4 ,
Paul E. Glaser 5 , Richard L. Rubin 6 , Elias S. Sarkis 7 , Teresa A. Pigott 8 , Bethany K. Boardman 2
1 Eli Lilly and Company, Istanbul,Turkey
2 Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA
3 Department of Psychiatry, NYU School of Medicine; and Psychiatry Service, New York VA Harbor Healthcare System, New York, NY, USA
4 UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA
5 University of Kentucky, Department of Psychiatry, Lexington, KY, USA,
6 Vermont Clinical Study Center, Burlington, VT, USA
7 Division of Child and Adolescent Psychiatry, University of Florida, Gainesville, FL, USA
8 Department of Psychiatry, University of Florida, Gainesville, FL, USA
E-mail: altin_murat@lilly.com
Objectives: ADHD in young adults is associated with significant impairment in multiple functional domains. This trial examined the
efficacy of atomoxetine (ATX) in young adults and evaluated improvements in core ADHD symptoms and associated functional outcomes.
Method: Patients aged 18-30 years were randomized to 12 weeks of double-blind treatment with ATX (n=220) or placebo (PBO, n=225).
Patients in the atomoxetine treatment arm began treatment with 40 mg/day (dosed 20 mg BID) for a minimum of 7 days followed by
S135